Oramed Pharmaceuticals Technology Patented with WIPO
13 September 2006 - 11:06PM
PR Newswire (US)
JERUSALEM, Sept. 13 /PRNewswire/ -- Oramed Pharmaceuticals is
excited to announce the patent application of a PCT (Patent
Cooperation Treaty) for the Methods and Compositions for Oral
Administration of Proteins has been approved and filed with WIPO
(World Intellectual Property Organization). The application was
filed on August 31, 2006, at the Israel Patent Office (IPO), acting
as Receiving Office for the WIPO. Priority was claimed from
60/713,716, all countries were designated and the United States
Patent and Trademark Office (USPTO) was designated as Search and
Examination Authority. This is expected to ensure global patent
protection for Oramed's proprietary technology to deliver insulin
orally. About WIPO The World Intellectual Property Organization
(WIPO) is a specialized agency of the United Nations. It is
dedicated to developing a balanced and accessible international
intellectual property (IP) system, which rewards creativity,
stimulates innovation and contributes to economic development while
safeguarding the public interest. The five strategic goals of WIPO
include: * To promote an IP culture; * To integrate IP into
national development policies and programs; * To develop
international IP laws and standards; * To deliver quality services
in global IP protection systems; and * To increase the efficiency
of WIPO's management and support processes. About Oramed
Pharmaceuticals: Oramed Pharmaceuticals is an Israeli based company
focused on the development of oral delivery solutions based on
proprietary technology. Diabetes is one of the most rapidly growing
diseases in the world and is one that requires constant and often
unpleasant monitoring and drug therapy regimen. Oramed is currently
developing an orally ingestible soft gel insulin capsule for the
treatment of diabetes. The Company is also pursuing the development
of oral delivery solutions for other drugs and vaccines. For more
information please visit our website at
http://www.oramedpharma.com/ Investor Relations Contact: Oramed
Pharmaceuticals, Inc. Vinisha Agnihotri (646) 467-2252
http://www.oramedpharma.com/ Legal Notice Regarding Forward Looking
Statements This news release contains statements, which may
constitute "forward- looking statements". Those statements include
statements regarding the intent, belief or current expectations of
Oramed Pharmaceutical Inc., and members of our management as well
as the assumptions on which such statements are based.
Forward-looking statements in this release include: that we are
currently developing an orally ingestible soft gel insulin capsule
for the treatment of diabetes and for other diseases; that our
approved patent will protect our proprietary technology; and the
potential of our future products relating to oral insulin. Factors
which may significantly change or prevent our forward looking
statements from fruition include that we may be unsuccessful in
developing any products; we may be unable to raise funds and
resources to pursue research and development, we may be unable to
successfully defend our patents from infringement by third parties,
there is a risk that our patent may be subsequently shown to be
invalid or infringe the patents of others, our products may never
gain FDA or other regulatory body approval for human consumption
and we may be unable to successfully commercialise our future
products. Readers should refer to our most recent 10-KSB filed on
Edgar and the 8-K announcing our acquisition of the Oramed
technology filed March 8, 2006. DATASOURCE: Oramed Pharmaceuticals
CONTACT: Vinisha Agnihotri, Investor Relations, of Oramed
Pharmaceuticals, Inc., +1-646-467-2252, Web site:
http://www.oramedpharma.com/
Copyright